EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Symbiotic exclusivity between CLOCK and TFPI2 drives stemness and immunosuppression in glioblastoma models

Fei Zhou, Lizhi Pang, Yang Liu, Fatima Khan, Peiwen Chen

Journal of Clinical Investigation · 2026

DOI: 10.1172/jci199056 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Fei Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Sciences, Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Glioblastoma, Neoplastic Stem Cells, Glycoproteins, Brain Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS, DoD, Cancer Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is a highly aggressive brain tumor characterized by extensive crosstalk between glioblastoma stem cells (GSCs) and immunosuppressive microglia, with our previous work identifying CLOCK and TFPI2 as key regulators of this interaction. Here, we uncover a ‘symbiotic exclusivity’ pattern between CLOCK and TFPI2, showing that, despite mutually exclusive amplifications, they sustain symbiotic regulatory interactions in GBM. The CLOCK-BMAL1 complex transcriptionally upregulates TFPI2, while TFPI2-driven hypoxia inducible factor 1 α (HIF-1α) signaling activates nuclear factor k B (NF-kB) P65 to upregulate the CLOCK-BMAL1 complex, creating a positive feedback loop to promote stemness, immunosuppression, and tumor progression. Disrupting the CLOCK-TFPI2 interplay through dual inhibition of their downstream effectors reduces GSC stemness and immunosuppressive microglia, activates antitumor immunity, and synergizes with anti-PD1 therapy to achieve complete tumor regression in 50%–62.5% of tumor-bearing mice. This study uncovers a promising therapeutic strategy for a broader subset of patients with GBM with high expression of either CLOCK or TFPI2, and provides a framework for identifying ‘symbiotic exclusivity’ genes in cancer. Scientists discovered two genes that cooperate to help aggressive brain tumors grow and evade immunity. Targeting both pathways boosts immune therapy and shrinks tumors in mice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaNeoplastic Stem CellsGlycoproteinsBrain NeoplasmsNeoplasm ProteinsAnimalsHumansMiceARNTL Transcription FactorsGene Expression Regulation, NeoplasticCell Line, Tumor

Stichwörter der Autor:innen

Adult stem cellsCancerImmunologyImmunotherapyOncology

Substanzen

Glycoproteinstissue-factor-pathway inhibitor 2ARNTL Transcription FactorsNeoplasm ProteinsBMAL1 protein, human

Autor:innen und Institutionen

  • Department of Cancer Sciences, Cleveland Clinic, Cleveland, Ohio, USA.
  • Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA.
  • Case Comprehensive Cancer Center, Cleveland, Ohio, USA.

Förderung

  • NINDS
  • DoD
  • Cancer Research Institute
  • VeloSano

Zitieren

APA

Zhou, F., Pang, L., Liu, Y., Khan, F., & Chen, P. (2026). Symbiotic exclusivity between CLOCK and TFPI2 drives stemness and immunosuppression in glioblastoma models. Journal of Clinical Investigation. https://doi.org/10.1172/jci199056

Vancouver

Zhou F, Pang L, Liu Y, Khan F, Chen P. Symbiotic exclusivity between CLOCK and TFPI2 drives stemness and immunosuppression in glioblastoma models. Journal of Clinical Investigation. 2026. doi:10.1172/jci199056

BibTeX
@article{Zhou2026,
  author = {Zhou, Fei and Pang, Lizhi and Liu, Yang and Khan, Fatima and Chen, Peiwen},
  title = {Symbiotic exclusivity between CLOCK and TFPI2 drives stemness and immunosuppression in glioblastoma models},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1172/jci199056}
}
Kostenlos starten →